Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
In8bio Inc
INABCurrent price
0.33 USD
+0.0046 USD (+1.41%)
Last closed
0.33 USD
Company
in8bio.com
ISIN
US45674E1091
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
20 777 316 USD
Yield for 12 month
-69.10 %
1Y
3Y
5Y
10Y
15Y
INAB
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company develops INB-300 and INB-500 that are in preclinical phase for treatment of acute myeloid leukemia, and other solid and hematological tumor types. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is based in New York, New York. Address: 350 5th Avenue, New York, NY, United States, 10118
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
7.38 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-2 501 000 USD
Last Year
-1 103 000 USD
Current Quarter
-631 000 USD
Last Quarter
-632 000 USD
Key Figures INAB
1 year
3 years
5 years
10 years
EBITDA
-30 632 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-77.64 %
PEG Ratio
–
Return On Equity TTM
-180.45 %
Wall Street Target Price
7.38 USD
Revenue TTM
–
Book Value
0.29 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-0.82 USD
Diluted Eps TTM
-0.82 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics INAB
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History INAB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation INAB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
-1.1529
Price Book MRQ
1.5254
Financials INAB
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators INAB
For 52 weeks
0.22 USD
2.48 USD
50 Day MA
0.32 USD
Shares Short Prior Month
176 510
200 Day MA
0.86 USD
Short Ratio
0.42
Shares Short
147 357
Short Percent
0.27 %
BeatStart